Net profit of Thyrocare Technologies rose 31.12% to Rs 26.67 crore in the quarter ended September 2024 as against Rs 20.34 crore during the previous quarter ended September 2023. Sales rose 19.84% to Rs 177.36 crore in the quarter ended September 2024 as against Rs 148.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales177.36148.00 20 OPM %27.0625.35 - PBDT49.8538.92 28 PBT36.7828.27 30 NP26.6720.34 31 Powered by Capital Market - Live News

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live News

Thyrocare Technologies announced the cessation of Neetin Shivajirao Desai (DIN No: 02622364) as Independent Director of the company with effect from 19 September 2024 on completion of second term. Powered by Capital Market - Live News

Thyrocare Technologies has signed a Business Transfer Agreement for purchase of the diagnostic and pathological services business of Vimta Labs. Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 crore in Q1 FY 2025.Powered by Capital Market - Live News

Thyrocare Technologies announced that the Annual General Meeting (AGM) of the company will be held on 23 August 2024.Powered by Capital Market - Live News